Christopher D Lao

  • 3278 Citations
  • 15 Scopus h-Index
20042021

Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Merkel Cell Carcinoma Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Safety Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Brain Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2005 2021

Research Output 2004 2017

  • 3278 Citations
  • 15 Scopus h-Index
  • 27 Article
  • 6 Letter
  • 5 Review article
  • 2 Comment/debate

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)

Kalinsky, K., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., Margolin, K. A., Leitao, M. M., Tarhini, A. A., Koon, H. B., Pecora, A. L., Jaslowski, A. J., Cohen, G. I., Kuzel, T. M., Lao, C. D. & Kirkwood, J. M. 2017 In : Cancer.

Research output: Contribution to journalArticle

Melanoma
Extremities
Neoplasms
Protein-Tyrosine Kinases
Disease-Free Survival
Merkel Cell Carcinoma
Clinical Trials
Neoplasms

Health-related quality of life results from the phase III CheckMate 067 study

Schadendorf, D. , Larkin, J. , Wolchok, J. , Hodi, F. S. , Chiarion-Sileni, V. , Gonzalez, R. , Rutkowski, P. , Grob, J. J. , Cowey, C. L. , Lao, C. , Wagstaff, J. , Callahan, M. K. , Postow, M. A. , Smylie, M. , Ferrucci, P. F. , Dummer, R. , Hill, A. , Taylor, F. , Sabater, J. , Walker, D. & 3 others Kotapati, S., Abernethy, A. & Long, G. V. Sep 1 2017 In : European Journal of Cancer. 82, p. 80-91 12 p.

Research output: Contribution to journalArticle

Quality of Life
Health
Melanoma
CTLA-4 Antigen
Monoclonal Antibodies

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study

Sekulic, A., Migden, M. R., Basset-Seguin, N., Garbe, C., Gesierich, A., Lao, C. D., Miller, C., Mortier, L., Murrell, D. F., Hamid, O., Quevedo, J. F., Hou, J., McKenna, E., Dimier, N., Williams, S., Schadendorf, D., Hauschild, A. & and for the ERIVANCE BCC Investigators May 16 2017 In : BMC Cancer. 17, 1, 332

Research output: Contribution to journalArticle

Basal Cell Carcinoma
Safety
Hedgehogs
United States Food and Drug Administration
Disease-Free Survival

Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis

Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W., Weber, J., Suijkerbuijk, K. P. M., Azevedo, S., Li, H., Reshef, D., Avila, A. & Reardon, D. A. Jun 1 2017 In : Oncologist. 22, 6, p. 709-718 10 p.

Research output: Contribution to journalArticle

Encephalitis
Nervous System
Melanoma
Pharmacovigilance
Meningitis